Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001854
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
1999-11-03
Brief Title:
Long-Term Therapy With Ribavirin for Chronic Hepatitis C
Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Long-Term Therapy With Ribavirin for Chronic Hepatitis C
Status:
COMPLETED
Status Verified Date:
2008-01-15
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chronic hepatitis C is a disease of the liver caused by the hepatitis C virus The disease can be serious and even fatal Approximately 25 of patients with chronic hepatitis C will develop cirrhosis and some of these patients will develop cancer of the liver or liver failure
Presently the disease is treated with a combination of alpha interferon or peginterferon antiviral and immune stimulating drugs and ribavirin an antiviral drug Alpha interferon is given by injection three times a week whereas peginterferon is given by injection only once a week Ribavirin is given as a tablet by mouth twice a day The combination therapy is given for 6 to months About half of the patients given these medications will receive a lasting benefit and many patients do not respond well to the combination therapy
This study will select up to 50 patients will chronic hepatitis C who have not responded to combination therapy or who could not stand the side effects associated with interferon or peginterferon therapy These subjects will be evaluated and undergo liver biopsy to determine their present liver condition If selected as subjects they will be started on single drug therapy with ribavirin The drug will be given orally twice a day at a dose based on the patients body weight
The patients will be followed on an out-patient basis They will we asked to return for regular check-ups and blood tests every 2 to 8 weeks for the duration of the study After 6 months the medication will be stopped or adjusted based on the results of the subjects blood tests liver enzymes A response is considered if a decrease of 50 or more of the initial liver enzyme alanine aminotransferase ALT is noted A complete response will be considered if liver enzymes return to normal levels
Therapy will be discontinued after 6 months if patients do not respond However patients that respond to the single drug therapy will continue to receive the medication at a decreased dose The patients will remain on an appropriate dose for up to 8 years with repeat liver biopsies at 2 4 and 8 years to assess progress
This study will determine if long-term therapy with ribavirin is safe and effective
Presently the disease is treated with a combination of alpha interferon or peginterferon antiviral and immune stimulating drugs and ribavirin an antiviral drug Alpha interferon is given by injection three times a week whereas peginterferon is given by injection only once a week Ribavirin is given as a tablet by mouth twice a day The combination therapy is given for 6 to months About half of the patients given these medications will receive a lasting benefit and many patients do not respond well to the combination therapy
This study will select up to 50 patients will chronic hepatitis C who have not responded to combination therapy or who could not stand the side effects associated with interferon or peginterferon therapy These subjects will be evaluated and undergo liver biopsy to determine their present liver condition If selected as subjects they will be started on single drug therapy with ribavirin The drug will be given orally twice a day at a dose based on the patients body weight
The patients will be followed on an out-patient basis They will we asked to return for regular check-ups and blood tests every 2 to 8 weeks for the duration of the study After 6 months the medication will be stopped or adjusted based on the results of the subjects blood tests liver enzymes A response is considered if a decrease of 50 or more of the initial liver enzyme alanine aminotransferase ALT is noted A complete response will be considered if liver enzymes return to normal levels
Therapy will be discontinued after 6 months if patients do not respond However patients that respond to the single drug therapy will continue to receive the medication at a decreased dose The patients will remain on an appropriate dose for up to 8 years with repeat liver biopsies at 2 4 and 8 years to assess progress
This study will determine if long-term therapy with ribavirin is safe and effective
Detailed Description:
Up to 50 patients with chronic hepatitis C will be treated for up to eight years with ribavirin an orally administered antiviral agent Patients will be chosen who have moderate to severe chronic hepatitis C who previously failed to have a sustained virological response to the combination of alpha interferon and ribavirin or who were intolerant to interferon therapy or who have significant contraindications to the use of interferon
After medical evaluation and liver biopsy patients will begin receiving ribavirin in a dose of 1000 mg body weight less than 75 K or 1200 mg daily two or three capsules of 200 mg twice daily by mouth Patients will be followed on therapy with visits to the outpatient clinic for medical interview physical examinations and blood tests at 2 to 8 week intervals After six months the dose of ribavirin will be stopped or adjusted based upon changes in alanine aminotransferase ALT levels comparing the average of the three values from month 2 4 and 6 to the baseline levels A decrease by 50 or more will be considered a partial biomedical response and a decrease to within the normal range will be considered a complete biochemical response In patients who do not respond by six months therapy will be stopped whereas in patients who respond therapy will be continued decreasing the dose in increments of 200 mg per day every 6 months as long as a biochemical response is maintained The minimal dose will be 400 mg per day In patients with a response therapy will be continued for up to 8 years with repeat liver biopsies and evaluations at 2 4 and 8 years
The primary criterion for success of therapy will be the degree of histologic improvement on liver biopsy at 2 4 and 8 years supportive secondary criteria will be improvements in ALT levels and in symptoms done at the same time points This open-label pilot study will allow for therapy of patients with resistant forms of chronic hepatitis C and will address whether long-term therapy with this agent is safe as well as whether prolonged monotherapy with ribavirin leads to sustained improvements in serum ALT levels whether these can be maintained using lower doses of ribavirin and whether the improvements reflect amelioration of the underlying liver disease as judged histologically
After medical evaluation and liver biopsy patients will begin receiving ribavirin in a dose of 1000 mg body weight less than 75 K or 1200 mg daily two or three capsules of 200 mg twice daily by mouth Patients will be followed on therapy with visits to the outpatient clinic for medical interview physical examinations and blood tests at 2 to 8 week intervals After six months the dose of ribavirin will be stopped or adjusted based upon changes in alanine aminotransferase ALT levels comparing the average of the three values from month 2 4 and 6 to the baseline levels A decrease by 50 or more will be considered a partial biomedical response and a decrease to within the normal range will be considered a complete biochemical response In patients who do not respond by six months therapy will be stopped whereas in patients who respond therapy will be continued decreasing the dose in increments of 200 mg per day every 6 months as long as a biochemical response is maintained The minimal dose will be 400 mg per day In patients with a response therapy will be continued for up to 8 years with repeat liver biopsies and evaluations at 2 4 and 8 years
The primary criterion for success of therapy will be the degree of histologic improvement on liver biopsy at 2 4 and 8 years supportive secondary criteria will be improvements in ALT levels and in symptoms done at the same time points This open-label pilot study will allow for therapy of patients with resistant forms of chronic hepatitis C and will address whether long-term therapy with this agent is safe as well as whether prolonged monotherapy with ribavirin leads to sustained improvements in serum ALT levels whether these can be maintained using lower doses of ribavirin and whether the improvements reflect amelioration of the underlying liver disease as judged histologically
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 99-DK-0042 | None | None | None |